Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of bevacizumab-IRDye 800CW fluorescence imaging in breast cancer surgery
NL-OMON39185Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of bevacizumab-IRDye800CW in breast cancer, sponsored by University Medical Center Groningen. Primary endpoints: Tracer uptake in surgical specimens and Safety and immunogenicity. Started Mar 2012; status: active, not recruiting.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON39185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39185.